$0.98
+0.00 (+0.27%)
Open$0.97
Previous Close$0.98
Day High$1.01
Day Low$0.94
52W High$2.57
52W Low$0.83
Volume—
Avg Volume642.8K
Market Cap63.31M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,062.1% upside
Current
$0.98
$0.98
Target
$11.39
$11.39
$7.11
$11.39 avg
$14.81
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.20M | 5.69M | 16.16M |
| Net Income | -65,344,280 | -64,371,554 | -2,032,977 |
| Profit Margin | -1,256.8% | -1,194.0% | -12.6% |
| EBITDA | -66,945,375 | -69,612,638 | -2,828,117 |
| Free Cash Flow | — | — | -1,769,464 |
| Rev Growth | -8.6% | -8.6% | -2.0% |
| Debt/Equity | 0.26 | 0.26 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |